# lung adenocarcinoma (LUAD) - grok-4.6

- Benchmark system: E2seq + Agent RAG
- Repeat: 3
- Task type: PROGNOSIS
- Tissue / sample source: lung adenocarcinoma tumor tissue
- Comparison or endpoint: overall survival (OS)
- Answer input cohort: Discovery/Core only
- Selected items: 100
- Input fields: gene name, effect size (log2FC/HR), P value, FDR
- E2seq Agent RAG: enabled
- Conversation memory: disabled
- Thinking mode: disabled
- Held-out validation data in prompt/RAG: no
- Model API: xAI / grok-4.6
- Message SHA-256: a2c9355177479f23c6c81afe1b39ba697ac131cc344bb83120b98e2c6bbfee49
- Response HTTP status: 200
- Prompt tokens: 69269
- Completion tokens: 29841
- Reasoning tokens: 20137
- Total tokens: 99110
- API requests reported: 6
- Elapsed seconds: 161.396
- RAG status: reused_or_ready
- RAG records/genes reported: 100
- RAG elapsed seconds: 957.651
- Question handoff seconds: 970.897
- Final benchmark system: E2seq; file rank 2/5; original repeat 3; model vendor: xAI

---
**Overall biological interpretation**  
The transcriptomic results indicate a strong prognostic risk signature in LUAD tumor tissue, with the large majority of selected genes (96/100) showing HR > 1 and extreme values (many > 5 × 10²¹). This pattern is dominated by non-coding RNAs, pseudogenes, and unannotated transcripts rather than a coherent set of protein-coding drivers. A minority of genes (TCP10L3, RBMXP1, CRNDE, CMAHP) are protective (HR < 1). The signal is consistent with known prognostic heterogeneity in LUAD but is limited by the predominance of uncharacterized elements.

**Core biological programs**  
No coherent biological programs can be identified from the input dataset alone. The 96 risk-associated genes are overwhelmingly unannotated pseudogenes or lncRNAs, preventing clustering into multiple independent, minimally redundant programs supported by the uploaded HR, P, and FDR statistics.  

Exploratory alternatives based on the few annotated protein-coding genes and external annotations:  
- **Cytoskeletal regulation and cell migration** (risk-associated). Major genes: RHOF, KRT6A. Pathway: Regulation of actin cytoskeleton organization (QuickGO). Supporting genes collectively point to motility and metastasis programs; RHOF (Rho GTPase) and KRT6A (epithelial intermediate filament) are co-expressed in actin-related processes. Evidence strength: moderate (external GO annotations only); limitation: only two genes with no direct physical interaction evidence.  
- **G-protein-coupled receptor signaling** (risk-associated). Major gene: RGS20. Pathway: G alpha (i/z) signalling events (Reactome). RGS20 acts as a negative regulator of G-protein signaling; single-gene support limits generalizability. Evidence strength: low; limitation: no additional cohort genes in the program.  
- **Transcriptional regulation** (mixed direction). Major genes: TLE1, PITX3. Pathway: General transcriptional repression (Hallmark-style). TLE1 (transcriptional repressor) and PITX3 (homeodomain factor) suggest regulatory control of proliferation genes, but redundancy with other unannotated elements prevents formal designation. Evidence strength: exploratory; limitation: single-gene per sub-module.

**Key genes and interaction modules**  
- **RHOF** (risk, HR = 1.403): Cytoskeletal regulation program; indirect relationship (co-expression/pathway co-membership) with KRT6A.  
- **KRT6A** (risk, HR = 1.390): Epithelial differentiation/migration; indirect relationship with RHOF via actin regulation.  
- **ITGB1-DT** (risk, HR = 1.302): Regulatory role in lncRNA networks; regulatory or co-expression interaction with other LUAD-associated lncRNAs (external literature support).  
- **DKK1** (risk, HR = 1.475): Wnt signaling; regulatory interaction with β-catenin (external annotation).  
- **RGS20** (risk, HR = 1.352): G-protein signaling; direct physical interaction with GNAZ/GNB5/GNAQ (STRING evidence).  
- **CRNDE** (protective, HR = 0.716): Cancer regulatory lncRNA; regulatory interaction in proliferation networks.  
- **CMAHP** (protective, HR = 0.706): Glycosphingolipid biosynthesis; pathway co-membership with FUT4.  
- **TLE1** (risk, HR = 1.484): Transcriptional repression; regulatory interaction with PITX3.  
- **LDLRAD3** (risk, HR = 1.420): Cell adhesion; indirect relationship with APP (STRING).  
- **PITX3** (risk, HR = 1.429): Transcription factor; regulatory role within transcriptional programs.

**Validation priorities**  
- **Mechanistic hypothesis**: RHOF-driven actin remodeling in LUAD metastasis. Why: literature links high RhoF to worse survival in myeloid malignancies and cytoskeletal roles. Evidence: HR and direction from dataset; external GO/REACTOME annotations. Next step: siRNA/CRISPR in LUAD cell lines followed by migration/invasion assays. Status: supported hypothesis.  
- **Biomarker**: CRNDE for OS stratification in LUAD. Why: protective HR, established lncRNA prognostic role in multiple cancers. Evidence: dataset statistic; external literature. Next step: RT-qPCR validation in independent LUAD cohort with OS correlation. Status: supported hypothesis.  
- **Interaction/network hypothesis**: RGS20–G-protein complex in LUAD proliferation. Why: STRING direct interactions plus Reactome pathway membership. Evidence: dataset HR; external protein–protein data. Next step: co-immunoprecipitation to test physical binding. Status: exploratory hypothesis.  
- **Confounding or composition check**: Tumor-purity effects on lncRNA/pseudogene HRs. Why: 96 risk genes are mostly non-coding and sensitive to stromal contamination. Evidence: dataset distribution; external TCGA purity metrics available. Next step: re-analysis with ESTIMATE or CIBERSORT-adjusted expression. Status: exploratory.  
- **Biomarker**: KRT6A as epithelial-mesenchymal transition marker in LUAD. Why: risk HR and known cytoskeletal role. Evidence: dataset; external literature on KRT6A in carcinomas. Next step: IHC validation in tumor tissue microarrays. Status: supported hypothesis.

**Evidence grounding**  
Uploaded HR, P, and FDR values constitute the sole direct statistical evidence for associations in this cohort. Pathway/ontology (QuickGO, Reactome), protein–regulatory (STRING), disease-association (PubMed), and tissue-specific (GTEx) records provide contextual plausibility for individual genes or modules but are not independent-cohort statistics and may overlap with publication sources. No genuine independent-cohort HR or replication statistic is supplied for any gene or program. Literature records (e.g., RHOF, ITGB1-DT) support plausibility but do not override or replace the input statistics. All pathway co-membership claims are distinguished from direct physical interaction (only STRING-confirmed edges qualify).

**Limitations and alternative explanations**  
- Tissue or cell-composition differences: lncRNA/pseudogene HRs can be confounded by stromal infiltration or varying tumor purity; distinguishable by correlating HRs with ESTIMATE scores or pathological purity estimates.  
- Association-versus-causation ambiguity: extreme HR values may reflect correlation rather than direct mechanistic contribution; experimental knockdown or CRISPR studies are required to test causality.  
- Batch or platform effects: extreme HR magnitudes (many > 10²¹) and high proportion of unannotated genes raise possibility of technical artifacts; distinguishable by batch-effect correction or platform-orthogonal validation.  
- Small subgroup effects: only four protective genes and limited OS events in subgroups may inflate HR instability; testable by bootstrap resampling or leave-one-out sensitivity analysis.  
- Nonspecific or absent pathway enrichment: no formal GSEA or enrichment was performed on the input gene list, so any program signal derives solely from external annotations and remains exploratory.

The current data therefore provide a statistically significant but biologically incomplete prognostic signature whose functional interpretation awaits targeted validation of the annotated subset of genes.

E2seq statistical audit: selected=100, ledger=100, RAG records=100, numeric claims checked=11, external claims checked=0, external mismatches=0, status=needs review.

Answer model API: xAI / grok-4.6

Source coverage (gene sources = selected items with records / selected RAG items; literature sources = articles / queries)
Online APIs: alliance 53/100 selected items (records returned); cbioportal 51/100 selected items (records returned); chembl 16/100 selected items (records returned); civic 1/100 selected items (records returned); clinicaltrials 6/100 selected items (records returned); clinvar 30/100 selected items (records returned); ensembl 11/100 selected items (partially returned; some queries failed); europepmc 362 articles / initial full-cohort RAG 100 queries + 4 current-round queries; some queries failed; gtex 81/100 selected items (records returned); gwas 100/100 selected items (records returned); hpa 14/100 selected items (records returned); humanbase 56/100 selected items (partially returned; some queries failed); intact 18/100 selected items (records returned); mygene 59/100 selected items (records returned); omnipath 3/100 selected items (records returned); opentargets 55/100 selected items (records returned); pubmed 202 articles / initial full-cohort RAG 100 queries + 3 current-round queries; quickgo 17/100 selected items (records returned); reactome 100/100 selected items (records returned); uniprot 17/100 selected items (records returned)
Local databases: gutmgene 0/100 selected items (reachable but no records for this batch); hmdb 2/100 selected items (records returned); string 14/100 selected items (records returned); trrust 4/100 selected items (records returned)
